05:58 PM EDT, 05/20/2024 (MT Newswires) -- Insmed ( INSM ) said Monday that patients with mycobacterial lung infection showed improvement in breathing with a combination of Arikayce and a macrolide-based regimen, compared with patients who received macrolide alone during a phase 3 trial.

Arikayce was first approved in September 2018 in the US to treat lung infections caused by mycobacterium avium complex who do not respond to conventional treatments. According to trial data presented Monday, breathing improved in 43.8% of the new or recurring patients in the Arikayce arm of the study, compared with a 33.3% of the patients who were only treated with macrolide-based medications.

Positive symptoms for patients in the Arikayce arm improved through six months and continued improvement one month off-treatment, the company said.

Insmed ( INSM ) shares were 3% up during Monday's regular session.

Price: 25.70, Change: +0.16, Percent Change: +0.63